tiprankstipranks
Intellia Therapeutics price target lowered to $42 from $58 at Baird
The Fly

Intellia Therapeutics price target lowered to $42 from $58 at Baird

Baird analyst Jack Allen lowered the firm’s price target on Intellia Therapeutics to $42 from $58 and keeps a Neutral rating on the shares. The analyst said overall, Intellia’s earnings updates were inline with expectations with the two lead products, NTLA-2001 and NTLA-2002, both set to see US INDs this year.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on NTLA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles